HIV Drug Resistance Profile in Clients Experiencing Treatment Failure After the Transition to a Dolutegravir-Based First-Line Antiretroviral Treatment Regimen in Mozambique
Authors:
- Nalia IsmaelNINalia Ismael
- Cidia HusseinCHCidia Hussein
- Cacildo MagulCMCacildo Magul
- Humberto InguaneHIHumberto Inguane
- Aleny CoutoACAleny Couto
- Amancio NhangaveANAmancio Nhangave
- Ana MuteerwaAMAna Muteerwa
- Mahoudo BonouMBMahoudo Bonou
- Artur RamosARArtur Ramos
- Peter Wesley YoungPYPeter Wesley Young
- Sonia ChilundoSCSonia Chilundo
- Rhoderick MachekanoRMRhoderick Machekano
Open Access
Abstract
Real-world data on HIV drug resistance (HIVDR) after transitioning to tenofovir disoproxil fumarate/lamivudine/dolutegravir (TLD) are limited. We assessed HIVDR rates and patterns in clients with virological failure (VF) after switching from an NNRTI-based regimen to TLD. A cross-sectional study was conducted in Gaza, Mozambique (August 2021–February 2022), including adults on first-line ART for ≥12 months who transitioned to TLD and had unsuppressed viral load (VL) ≥ 1000 copies/mL six months post-transition. After three adherence counseling sessions, participants with VF underwent genotyping for drug resistance mutations (DRMs) using the Stanford HIVdb Program. Of 717 participants (median age 39.2 years, 70.7% female), 217 (30.2%) had VF, 193 (88.9%) underwent genotyping, with 183 (94.8%) successfully genotyped. Intermediate–high dolutegravir (DTG) resistance was found in 19.6% (36/183). Unsuppressed VL before DTG transition was independently associated with VF (aOR: 2.14). Resistance patterns included 33.3% (12/36; 95% CI: 14.6–46.3) to all three TLD drugs, 55.6% (20/36; 95% CI: 39.3–71.9) to DTG and 3TC, and 11% (4/36; 95% CI: 0.8–21.3) to DTG only. Major drug resistance mutations to DTG included G118R (9.3%), R263K (6.6%), and Q148H/R/K (4.4%). This study highlights the need to consider virologic status before transitioning PLHIV to TLD and suggests that adherence counseling may not prevent resistance in those with unknown or prior VF.Keywords
Funding Information
- U.S. President’s Emergency Plan for AIDS Relief (PEPFAR) (#NU2GGH001945)
This publication has 32 references indexed in Scilit:
- HIV-1 diversity and pre-treatment drug resistance in the era of integrase inhibitor among newly diagnosed ART-naïve adult patients in Luanda, AngolaScientific Reports, 2024
- Switch to long-acting cabotegravir and rilpivirine in virologically suppressed adults with HIV in Africa (CARES): week 48 results from a randomised, multicentre, open-label, non-inferiority trialThe Lancet Infectious Diseases, 2024
- HIV-1 drug resistance in people on dolutegravir-based antiretroviral therapy: a collaborative cohort analysisThe Lancet HIV, 2023
- The potential role of long-acting injectable cabotegravir–rilpivirine in the treatment of HIV in sub-Saharan Africa: a modelling analysisThe Lancet Global Health, 2021
- Reduced efficacy of HIV-1 integrase inhibitors in patients with drug resistance mutations in reverse transcriptaseNature Communications, 2020
- Differences among HIV-1 subtypes in drug resistance against integrase inhibitorsInfection, Genetics and Evolution, 2016
- Automated subtyping of HIV-1 genetic sequences for clinical and surveillance purposes: Performance evaluation of the new REGA version 3 and seven other toolsInfection, Genetics and Evolution, 2013
- Genetic Diversity and Naturally Polymorphisms in HIV Type 1 Integrase Isolates from Maputo, Mozambique: Implications for Integrase InhibitorsAIDS Research and Human Retroviruses, 2012
- Abbott RealTime HIV-1 m2000rt viral load testing: Manual extraction versus the automated m2000sp extractionJournal of Virological Methods, 2011
- Fifteen years of HIV Protease Inhibitors: raising the barrier to resistanceAntiviral Research, 2010